Clinical Trial Update: Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors [Phase 1, Phase 2]

View source ↗

Summary

The document reports a completed Phase 1/Phase 2 trial evaluating Lutetium-177 dotatate in combination with metronomic capecitabine for aggressive gastroenterop…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor
• Neuroendocrine Tumor

Drugs mentioned

• LUTATHERA (Lutetium Lu-177 dotatate)
• Xeloda (capecitabine)

Snippet

Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Conditions: Neuroendocrine Tumors, Gastro Entero Pancreatic Neuroendocrine Tumors | Phase 1, Phase 2 | Status: COMPLETED